Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sichuan Univ. GPR68 compound 18l: sourced facts only. name: "Structure-activity relationship (SAR) of these compounds was analyzed, which led to the identification of a potent GPR68 antagonist (18l) with an IC50 value of 0.081 ± 0.006 μM." [PMID:41610652]; target: "Structure-activity relationship (SAR) of these compounds was analyzed, which led to the identification of a potent GPR68 antagonist (18l) with an IC50 value of 0.081 ± 0.006 μM." [PMID:41610652]; developer: "Key Laboratory of Drug Targeting and Drug Delivery System of Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, 610041, China." [PMID:41610652]; stage: "In a dextran sulfate sodium (DSS)-induced mouse model of IBD, 18l effectively alleviated disease symptoms." [PMID:41610652]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sichuan Univ. GPR68 compound 18l.